Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

Thyroid Nodule Classification and Management

Characteristics of Thyroid Nodules

  • Bordered and regular nodules are associated with benign lesions and low risk of malignancy, as defined by the American College of Radiology 1
  • Partially cystic nodules have a lower risk of malignity compared to completely solid nodules, according to the American Thyroid Association 1
  • The absence of central vascularization on Doppler ultrasound is a reassuring finding, as central chaotic vascularization is a suspicious characteristic, as noted by the Society of Radiologists in Ultrasound 1

TIRADS Classification and Management

  • The TIRADS 3 classification is based on the nodule being heterogeneous with a cystic component but without defined suspicious ultrasound characteristics, as stated by the American College of Endocrinology 2
  • Fine-needle aspiration (FNA) is not recommended for TIRADS 3 nodules unless there are additional clinical risk factors, according to the American Thyroid Association 2
  • The current guidelines prioritize surveillance for nodules less than 1 cm without suspicious characteristics, and this conservative approach extends to larger TIRADS 3 nodules, as recommended by the Endocrine Society 3, 4

Indications for Fine-needle Aspiration

  • FNA is indicated if the patient has a history of cervical or cephalic irradiation, as recommended by the American College of Radiology 2
  • FNA is also indicated if the patient has suspicious cervical adenopathies, a subcapsular nodule location, or documented rapid growth during follow-up, according to the Society of Radiologists in Ultrasound 2

Surveillance Protocol

  • A follow-up ultrasound should be performed at 12 months to evaluate nodule stability, as recommended by the American Thyroid Association 2
  • If the nodule remains stable in size and ultrasound characteristics, surveillance should continue at 12-24 month intervals, according to the American College of Endocrinology 2